Literature DB >> 29764789

Eosinophilic Otitis Media Treated with Anti-IgE Monoclonal Antibodies and A Bone Conduction Implant.

Young Eun Han1, Yong Seok Kang1, Younhoon Cho1, Moo Kyun Park1.   

Abstract

Eosinophilic otitis media (EOM) are intractable otitis media characterized by highly viscous secretions containing eosinophils in the middle ear. They are resistant to conventional medication and surgery. This condition occurs primarily in patients with bronchial asthma or allergic rhinitis and is often complicated by rhinosinusitis. Systemic and topical steroid therapies are effective treatments. However, long-term steroid therapy is often limited by a high risk of serious adverse effects. The use of topical steroids and otorrhea are bothersome when wearing hearing aids. Here, we report a case of intractable otitis media due to EOM. Otorrhea was controlled with topical steroids. Bone conduction hearing was stable for an extended period with anti-IgE monoclonal antibodies (omalizumab). An implantable bone conduction hearing aid was used for rehabilitation of conductive hearing loss.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29764789      PMCID: PMC6354496          DOI: 10.5152/iao.2018.4517

Source DB:  PubMed          Journal:  J Int Adv Otol        ISSN: 1308-7649            Impact factor:   1.017


  9 in total

1.  Cochlear implantation in deaf patients with eosinophilic otitis media using subtotal petrosectomy and mastoid obliteration.

Authors:  Hisashi Sugimoto; Miyako Hatano; Masao Noda; Hiroki Hasegawa; Tomokazu Yoshizaki
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-05-11       Impact factor: 2.503

2.  Eosinophilic Otitis Media.

Authors:  Hugo Lara-Sánchez; Luis A Vallejo
Journal:  N Engl J Med       Date:  2017-02-16       Impact factor: 91.245

3.  Clinical efficacy of anti-IgE therapy for eosinophilic otitis media.

Authors:  Yukiko Iino; Mariko Hara; Masayo Hasegawa; Shingo Matsuzawa; Akihiro Shinnabe; Hiromi Kanazawa; Naohiro Yoshida
Journal:  Otol Neurotol       Date:  2012-09       Impact factor: 2.311

Review 4.  Role of IgE in eosinophilic otitis media.

Authors:  Yukiko Iino
Journal:  Allergol Int       Date:  2010-07-25       Impact factor: 5.836

5.  Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease.

Authors:  Yukiko Iino; Sachiko Tomioka-Matsutani; Atsushi Matsubara; Takashi Nakagawa; Manabu Nonaka
Journal:  Auris Nasus Larynx       Date:  2011-01-19       Impact factor: 1.863

Review 6.  The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.

Authors:  Stephen Holgate; Thomas Casale; Sally Wenzel; Jean Bousquet; Yamo Deniz; Colin Reisner
Journal:  J Allergy Clin Immunol       Date:  2005-03       Impact factor: 10.793

7.  Comparison between a new implantable transcutaneous bone conductor and percutaneous bone-conduction hearing implant.

Authors:  Myrthe K S Hol; Rik C Nelissen; Martijn J H Agterberg; Cor W R J Cremers; Ad F M Snik
Journal:  Otol Neurotol       Date:  2013-08       Impact factor: 2.311

Review 8.  Eosinophilic otitis media: a new middle ear disease entity.

Authors:  Yukiko Iino
Journal:  Curr Allergy Asthma Rep       Date:  2008-11       Impact factor: 4.806

9.  A Case of Severe Asthma with Eosinophilic Otitis Media Successfully Treated with Anti-IgE Monoclonal Antibody Omalizumab.

Authors:  Azusa Okude; Etsuko Tagaya; Mitsuko Kondo; Manabu Nonaka; Jun Tamaoki
Journal:  Case Rep Pulmonol       Date:  2012-11-25
  9 in total
  1 in total

1.  Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP.

Authors:  Eugenio De Corso; Claudio Montuori; Stefano Settimi; Dario Antonio Mele; Alessandro Cantiani; Marco Corbò; Elena Cantone; Gaetano Paludetti; Jacopo Galli
Journal:  J Clin Med       Date:  2022-02-10       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.